Credit Suisse analyst Alethia Young noted that Sarepta (SRPT) shares have been weak since UnitedHealth (UNH) posted its medical benefit policy for the company's DMD drug Exondys 51, but she doesn't see a reason for the weakness. She doesn't think encouraging home infusions limits access and believes the requirement for an every 6 month reauthorization is neither "prohibitive nor concerning" as it is standard with expensive rare disease treatments. She sees the policy as a positive for Sarepta, as having more payers supporting Exondys reimbursement makes it hard for other payers not to do so, and keeps an Outperform rating on Sarepta shares.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here